T1	PROC 59 115	evaluar el efecto de la reducción progresiva de la dosis
T2	CHEM 119 129	filgotinib
#1	AnnotatorNotes T2	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T3	LIVB 133 142	pacientes
#2	AnnotatorNotes T3	C0030705; Patients; Patient or Disabled Group
T4	DISO 147 163	colitis ulcerosa
#3	AnnotatorNotes T4	C0009324; Ulcerative Colitis; Disease or Syndrome
T5	PROC 198 259	Estudio aleatorizado, doble ciego, controlado y multicéntrico
T6	PROC 265 338	evaluar la eficacia y la seguridad de la reducción progresiva de la dosis
T8	CHEM 342 352	filgotinib
#4	AnnotatorNotes T8	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T10	Route 370 378	vía oral
T11	LIVB 382 391	pacientes
#5	AnnotatorNotes T11	C0030705; Patients; Patient or Disabled Group
T12	DISO 396 412	colitis ulcerosa
#6	AnnotatorNotes T12	C0009324; Ulcerative Colitis; Disease or Syndrome
T13	DISO 456 472	colitis ulcerosa
#7	AnnotatorNotes T13	C0009324; Ulcerative Colitis; Disease or Syndrome
T14	LIVB 505 514	pacientes
#8	AnnotatorNotes T14	C0030705; Patients; Patient or Disabled Group
T15	Date 578 589	actualmente
T16	PROC 590 601	tratamiento
#9	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	Dose 606 612	200 mg
T18	CHEM 616 626	filgotinib
#10	AnnotatorNotes T18	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T20	Frequency 630 632	/d
T21	DISO 688 692	pMCS
T22	PROC 727 734	visitas
T23	Frequency 735 747	trimestrales
T25	Neg_cue 847 850	sin
T26	CHEM 851 868	corticoesteroides
#11	AnnotatorNotes T26	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T27	Negated 851 868	corticoesteroides
T28	Duration 877 896	al menos 12 semanas
T29	PROC 929 932	CPF
T30	PROC 958 969	observación
#12	AnnotatorNotes T30	C0302523; Observation in research; Research Activity | C0700325; Patient observation; Health Care Activity
T31	PROC 973 975	PE
#13	AnnotatorNotes T31	C0015260; Exercise stress test; Diagnostic Procedure
T32	PROC 982 996	sigmoidoscopia
#14	AnnotatorNotes T32	C0037075; Sigmoidoscopy (procedure); Diagnostic Procedure
T33	LIVB 1048 1057	pacientes
#15	AnnotatorNotes T33	C0030705; Patients; Patient or Disabled Group
T34	PHYS 1075 1083	concebir
#16	AnnotatorNotes T34	C0009637; Conception; Organism Function
T35	Neg_cue 1109 1117	negativo
T36	PROC 1125 1143	prueba de embarazo
#17	AnnotatorNotes T36	C0032976; Pregnancy Tests; Diagnostic Procedure
T37	Negated 1135 1143	embarazo
T38	PROC 1164 1208	gonadotropina coriónica humana beta en suero
T39	Frequency 1257 1269	mensualmente
T40	PROC 1276 1294	prueba de embarazo
#18	AnnotatorNotes T40	C0032976; Pregnancy Tests; Diagnostic Procedure
T42	PROC 1299 1321	tira reactiva de orina
T43	PROC 1333 1344	tratamiento
#19	AnnotatorNotes T43	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T44	CHEM 1349 1359	filgotinib
#20	AnnotatorNotes T44	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T45	LIVB 1367 1394	pacientes de sexo masculino
T46	LIVB 1401 1427	pacientes de sexo femenino
T47	PHYS 1445 1453	concebir
#21	AnnotatorNotes T47	C0009637; Conception; Organism Function
T48	PROC 1478 1501	métodos anticonceptivos
#22	AnnotatorNotes T48	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T49	PROC 1549 1558	protocolo
#23	AnnotatorNotes T49	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T50	Neg_cue 1579 1585	evitar
T51	CHEM 1594 1648	vacunas elaboradas con microorganismos vivos atenuados
T52	Negated 1594 1648	vacunas elaboradas con microorganismos vivos atenuados
T53	Duration 1678 1688	12 semanas
T55	CHEM 1713 1723	filgotinib
#24	AnnotatorNotes T55	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T56	DISO 1843 1866	afección médica crónica
T57	Duration 1859 1866	crónica
T58	DISO 1881 1891	neumopatía
#25	AnnotatorNotes T58	C0024115; Lung diseases; Disease or Syndrome
T59	DISO 1894 1905	cardiopatía
#26	AnnotatorNotes T59	C0018799; Heart Diseases; Disease or Syndrome
T60	DISO 1907 1918	alcoholismo
#27	AnnotatorNotes T60	C0001973; Alcoholic Intoxication, Chronic; Mental or Behavioral Dysfunction
T61	DISO 1921 1933	drogadicción
#28	AnnotatorNotes T61	C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T62	LIVB 1955 1967	investigador
#29	AnnotatorNotes T62	C0035173; Research Personnel; Professional or Occupational Group
T63	LIVB 1995 2003	paciente
#30	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	Neg_cue 2004 2006	no
T65	Negated 2011 2031	apto para el estudio
T66	Neg_cue 2034 2040	impida
T67	Negated 2044 2070	cumplimiento del protocolo
T68	PROC 2044 2070	cumplimiento del protocolo
#31	AnnotatorNotes T68	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T69	LIVB 2087 2095	paciente
#32	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	DISO 2102 2119	hipersensibilidad
#33	AnnotatorNotes T70	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding | C0585186; Cutaneous hypersensitivity; Disease or Syndrome
T71	CHEM 2135 2161	ingredientes de filgotinib
T72	DISO 2184 2201	reacción alérgica
#34	AnnotatorNotes T72	C0020517; Hypersensitivity; Pathologic Function | C1527304; Allergic Reaction; Pathologic Function
T73	CHEM 2222 2248	ingredientes de filgotinib
T74	LIVB 2277 2289	investigador
#35	AnnotatorNotes T74	C0035173; Research Personnel; Professional or Occupational Group
T75	LIVB 2293 2335	Mujer embarazada o en período de lactancia
T76	PHYS 2379 2388	amamantar
#36	AnnotatorNotes T76	C0006147; Breast Feeding; Organism Function
T77	PROC 2429 2437	donación
T78	PROC 2440 2460	extracción de óvulos
T79	PHYS 2474 2485	fecundación
#37	AnnotatorNotes T79	C0015914; Fertilization; Organism Function
T80	Date 2486 2492	actual
T81	Date 2495 2501	futura
T82	LIVB 2552 2559	Hombres
#38	AnnotatorNotes T82	C0025266; Male population group; Population Group | C0086418; Homo sapiens; Human
T83	Neg_cue 2564 2566	no
T85	PROC 2600 2611	donar semen
T86	Negated 2600 2611	donar semen
T87	Duration 2620 2636	al menos 90 días
T88	Date 2651 2663	última dosis
T89	CHEM 2668 2693	producto en investigación
T90	CHEM 2695 2698	PEI
T91	LIVB 2706 2714	paciente
#39	AnnotatorNotes T91	C0030705; Patients; Patient or Disabled Group
T92	Neg_cue 2726 2728	no
T93	Negated 2746 2775	cumplir con las restricciones
T94	CHEM 2791 2801	medicación
#40	AnnotatorNotes T94	C0013227; Pharmaceutical Preparations; Pharmacologic Substance
T95	PROC 2854 2863	protocolo
#41	AnnotatorNotes T95	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T96	LIVB 2870 2878	paciente
#42	AnnotatorNotes T96	C0030705; Patients; Patient or Disabled Group
T97	PROC 2913 2953	prueba de tuberculosis (TB) QuantiFERON®
T98	PROC 3006 3030	prueba de TB QuantiFERON
T99	PROC 3049 3077	interrupción del tratamiento
T100	CHEM 3085 3088	PEI
T101	DISO 3108 3125	neoplasia maligna
#43	AnnotatorNotes T101	C0006826; Malignant Neoplasms; Neoplastic Process | C1306459; Primary malignant neoplasm; Neoplastic Process
T102	Neg_cue 3127 3134	excepto
T103	LIVB 3135 3144	pacientes
#44	AnnotatorNotes T103	C0030705; Patients; Patient or Disabled Group
T104	Negated 3135 3144	pacientes
T105	PROC 3145 3153	tratados
T107	DISO 3181 3195	cáncer de piel
#45	AnnotatorNotes T107	C0007114; Malignant neoplasm of skin; Neoplastic Process | C0699893; Skin carcinoma; Neoplastic Process
T108	Negated 3196 3204	distinto
T109	Negated 3209 3217	melanoma
#46	AnnotatorNotes T109	C0025202; melanoma; Neoplastic Process
T110	DISO 3223 3255	carcinoma cervicouterino in situ
#47	AnnotatorNotes T110	C0851140; Carcinoma in situ of uterine cervix; Neoplastic Process
T111	Negated 3223 3255	carcinoma cervicouterino in situ
T112	LIVB 3262 3270	paciente
#48	AnnotatorNotes T112	C0030705; Patients; Patient or Disabled Group
T113	PROC 46 53	Estudio
T114	PROC 813 822	selección
T115	PROC 1221 1230	selección
T41	PROC 1660 1667	estudio
T116	PROC 1730 1737	estudio
T117	LIVB 1973 1981	promotor
T118	PHYS 2363 2373	embarazada
T119	PROC 2514 2521	estudio
T106	DISO 3209 3217	melanoma
T120	PROC 3295 3319	interrupción del estudio
T7	Dose 627 630	1 v
T9	PROC 2960 2969	selección
